» Articles » PMID: 29262809

Using Medication Utilization Information to Develop an Asthma Severity Classification Model

Overview
Publisher Biomed Central
Date 2017 Dec 22
PMID 29262809
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Claims data are currently widely used as source data in asthma studies. However, the insufficient information in claims data related to level of asthma severity may negatively impact study findings. The present study develops and validates an asthma severity classification model that uses medication utilization in Taiwan National Health Insurance claims data.

Methods: The National Health Insurance Research Database was used for the years 2006-2012 and included a total of 7221 patients newly diagnosed with asthma in 2007 for model development and in 2008 for model validation. The medication utilization of patients during the first year after the index date was used to classify level of severity, and the acute exacerbation of asthma during the second through fourth years after the index date was used as the outcome variable. Three models were developed, with subjects classified into four, three, and two groups, respectively. The area under the receiver operating characteristic curve (AUC) and the Kaplan-Meier survival curve were used to compare the performances of the classification models.

Results: In development data, the distribution of subjects and acute exacerbation rate among the stage 1 to stage 4 were: 62.71%, 5.54%, 22.79%, and 8.96%, and 8.17%, 9.55%, 11.97%, and 14.91%, respectively. The results also showed the higher severity groups to be more prone to being prescribed oral corticosteroids for asthma control, while lower severity groups were more likely to be prescribed short-acting medication and inhaled corticosteroid treatment. Furthermore, the results of survival analysis showed two-group classification was recommended and yield moderate performance (AUC = 0.671). In validation data, the distribution of subjects, acute exacerbation rates, and medication uses among stages were similar to those in development data, and the results of survival analysis were also the same.

Conclusions: Understanding asthma severity is critical to conducting effective, scholarly research on asthma, which currently uses claims data as a primary data source. The model developed in the present study not only overcomes a gap in the current literature but also provides an opportunity to improve the validity and quality of claims-data-based asthma studies.

Citing Articles

Can markers of disease severity improve the predictive power of claims-based multimorbidity indices?.

Rizzo A, Jing B, Boscardin W, Shah S, Steinman M J Am Geriatr Soc. 2022; 71(3):845-857.

PMID: 36495264 PMC: 10023343. DOI: 10.1111/jgs.18150.

References
1.
Koshak E . Classification of asthma according to revised 2006 GINA: evolution from severity to control. Ann Thorac Med. 2009; 2(2):45-6. PMC: 2732074. DOI: 10.4103/1817-1737.32228. View

2.
Chang H, Cheng H, Yen H, Hsu C, Lee Y, Chiang J . Association between chronic idiopathic urticaria and hypertension: A population-based retrospective cohort study. Ann Allergy Asthma Immunol. 2016; 116(6):554-8. DOI: 10.1016/j.anai.2016.04.001. View

3.
Barnett S, Nurmagambetov T . Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol. 2011; 127(1):145-52. DOI: 10.1016/j.jaci.2010.10.020. View

4.
Erickson S, Kirking D . Variation in the distribution of patient-reported outcomes based on different definitions of defining asthma severity. Curr Med Res Opin. 2005; 20(12):1863-72. DOI: 10.1185/030079904X11529. View

5.
Yu T, Hou Y, Lin K, Chung K . Is it possible to identify cases of coronary artery bypass graft postoperative surgical site infection accurately from claims data?. BMC Med Inform Decis Mak. 2014; 14:42. PMC: 4050397. DOI: 10.1186/1472-6947-14-42. View